Physician profile
Narendra Tohan
NPI 1356382212
$3,845.94
in general payments reported to CMS, 2019-2025
15 companies · $468 in 2025
The $468 reported for 2025 was more than what 86% of Reproductive Endocrinology providers received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,153 · 2020: $596 · 2021: $354 · 2022: $542 · 2023: $119 · 2024: $614 · 2025: $468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,200.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,238.40 | 2019-2025 | Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $971.26 | 2019-2021 | |
| Esperion Therapeutics, INC. | $267.49 | 2020-2021 | |
| Exact Sciences Corporation | $164.40 | 2023-2024 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $160.82 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $158.10 | 2022 | |
| Novartis Pharmaceuticals Corporation | $141.93 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2024 | Jardiance |
| Medtronic, INC. | $123.75 | 2022 | |
| Intuitive Surgical, INC. | $121.23 | 2024 | |
| Olympus America INC. | $120.29 | 2019 | |
| Alexion Pharmaceuticals, INC. | $105.04 | 2019 | |
| Merck Sharp & Dohme LLC | $102.99 | 2019 | |
| Pfizer INC. | $23.34 | 2023 | |
| Arbor Pharmaceuticals, INC. | $21.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Narendra Tohan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.